Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Roche Holdings Ltd ADR (RHHBY)

Roche Holdings Ltd ADR (RHHBY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Is a Beat Likely for AbbVie (ABBV) This Earnings Season?

AbbVie's (ABBV) second-quarter results are expected to reflect the impact of strong demand for new drugs. Investors are likely to focus on any update related to guidance.

RHHBY : 47.2000 (+0.94%)
JNJ : 172.26 (+0.23%)
PFE : 42.10 (+0.69%)
ABBV : 117.63 (-0.14%)
Pharma Stock Roundup: JNJ, NVS Q2 Earnings, PFE, ABBV, LLY & MRK FDA Updates

J&J (JNJ) and Novartis (NVS) announce Q2 results. FDA delays decisions on JAK inhibitor drugs of Lilly (LLY), AbbVie (ABBV) and Pfizer (PFE) for eczema indication.

GSK : 39.53 (+1.31%)
NVS : 91.21 (+0.27%)
RHHBY : 47.2000 (+0.94%)
JNJ : 172.26 (+0.23%)
PFE : 42.10 (+0.69%)
LLY : 243.38 (+0.07%)
ABBV : 117.63 (-0.14%)
Roche's (RHHBY) 1H21 Sales Rise Despite Impact of Biosimilars

Roche's (RHHBY) performance in first-half 2021 was impressive on strong demand for new medicines and COVID-19 test kits. Impact of biosimilars continues to hurt sales.

REGN : 575.63 (-0.37%)
NVS : 91.21 (+0.27%)
RHHBY : 47.2000 (+0.94%)
ABBV : 117.63 (-0.14%)
Biogen (BIIB) Q2 Earnings Top, Aduhelm Early Sales Hit $2M

Biogen (BIIB) beats second-quarter estimates for both earnings and sales and ups sales guidance for 2021.

BIIB : 332.86 (+0.28%)
RHHBY : 47.2000 (+0.94%)
JNJ : 172.26 (+0.23%)
MRK : 77.70 (+0.60%)
AbbVie (ABBV) Venclexta Gets Breakthrough Therapy Tag for MDS

The FDA grants a Breakthrough Therapy designation to AbbVie's (ABBV) Venclexta in combination with azacitidine for treating adult patients with higher risk myelodysplastic syndrome.

RHHBY : 47.2000 (+0.94%)
JNJ : 172.26 (+0.23%)
ALXN : 182.50 (+1.70%)
ABBV : 117.63 (-0.14%)
Regeneron's (REGN) Antibody Cocktail for COVID-19 Approved in Japan

Regeneron's(REGN) cocktail for the treatment of COVID-19 gets approval in Japan as Ronapreve.

REGN : 575.63 (-0.37%)
GSK : 39.53 (+1.31%)
RHHBY : 47.2000 (+0.94%)
VIR : 36.41 (-1.51%)
Bayer's (BAYRY) Parkinson's Disease Therapy Gets Fast Track Tag

The FDA grants a Fast Track status to Bayer's (BAYRY) DA01 cell therapy which is being developed for the treatment of Parkinson's disease.

RHHBY : 47.2000 (+0.94%)
ALXN : 182.50 (+1.70%)
BAYRY : 14.8840 (-1.57%)
RGEN : 221.69 (+7.61%)
Bristol Myers' (BMY) Opdivo+Yervoy Fails First-Line SCCHN Study

Bristol Myers' (BMY) late-stage study evaluating Opdivo in combination with Yervoy as a first-line treatment for squamous cell carcinoma of the head and neck fails to meet goal.

RHHBY : 47.2000 (+0.94%)
BMY : 67.27 (-0.62%)
MRK : 77.70 (+0.60%)
RGEN : 221.69 (+7.61%)
BioMarin (BMRN) Gets EMA Validation for Hemophilia Gene Therapy

The EMA validates BioMarin's (BMRN) marketing application for valoctocogene roxaparvovec to treat adult patients with severe hemophilia A.

RHHBY : 47.2000 (+0.94%)
PFE : 42.10 (+0.69%)
BMRN : 77.93 (+0.75%)
SGMO : 9.65 (-0.21%)
Lilly's (LLY) Protomer Acquisition to Expand Diabetes Pipeline

Lilly (LLY), which holds a 14% stake in private biotech company Protomer, acquires the remaining interest in it. The acquisition is set to expand Lilly's diabetes pipeline.

RHHBY : 47.2000 (+0.94%)
LLY : 243.38 (+0.07%)
CORT : 19.94 (-0.99%)
CTLT : 113.10 (+0.09%)
J&J (JNJ) Recalls Some Sunscreens Due to Benzene Presence

J&J (JNJ) withdraws five aerosol sunscreen products from the market due to "low levels" of benzene found in some samples.

RHHBY : 47.2000 (+0.94%)
JNJ : 172.26 (+0.23%)
CTLT : 113.10 (+0.09%)
ADXN : 9.40 (-2.08%)
AstraZeneca (AZN) Gets Clearance in UK for Alexion Acquisition

AstraZeneca (AZN) obtains UK Competition and Markets Authority's permission for the impending acquisition of Alexion. The deal is expected to close on Jul 21, 2021.

AZN : 57.37 (+1.02%)
RHHBY : 47.2000 (+0.94%)
ALXN : 182.50 (+1.70%)
BAYRY : 14.8840 (-1.57%)
Celldex (CLDX) Up Almost 40% Since Skin Disorder Study Data

Celldex (CLDX) announces 95% response rate in urticaria patients in an early-stage study evaluating a single dose of its antibody candidate, CDX-0159. Shares are up almost 40% since last Friday.

NVS : 91.21 (+0.27%)
RHHBY : 47.2000 (+0.94%)
MRK : 77.70 (+0.60%)
CLDX : 42.39 (-2.28%)
Prothena (PRTA) to Sell ATTR Amyloidosis Program to Novo Nordisk

Prothena (PRTA) announces an agreement to sell its clinical-stage antibody, PRX004, and the broader ATTR amyloidosis program for $1.2 billion to Novo Nordisk.

BIIB : 332.86 (+0.28%)
RHHBY : 47.2000 (+0.94%)
NVO : 89.44 (+0.19%)
PRTA : 45.48 (-11.66%)
Sigilon (SGTX) Down as FDA Places Hold on Hemophilia Study

Sigilon (SGTX) stock declines as the FDA puts a clinical hold on its early/mid-stage hemophilia A study that was evaluating its lead candidate SIG-001.

RHHBY : 47.2000 (+0.94%)
NVO : 89.44 (+0.19%)
ZTS : 201.16 (+0.17%)
SGTX : 5.23 (+4.18%)
Biogen (BIIB) Gets FDA Nod for Narrow Label of Aduhelm

The FDA approves label update for Biogen's (BIIB) new Alzheimer's drug, Aduhelm. The updated label narrows the patient population, which is eligible for the drug.

NVS : 91.21 (+0.27%)
BIIB : 332.86 (+0.28%)
RHHBY : 47.2000 (+0.94%)
AMGN : 244.09 (-0.40%)
WHO Guidelines Put Spotlight on Arthritis Drugs Actemra & Kevzara

The latest guideline update by the WHO includes the use of arthritis drugs like Roche's (RHHBY) Actemra and Sanofi's (SNY) Kevzara for the treatment of severe COVID-19.

REGN : 575.63 (-0.37%)
SNY : 51.52 (-0.21%)
RHHBY : 47.2000 (+0.94%)
LLY : 243.38 (+0.07%)
Former Magenta Therapeutics and Foundation Medicine CFO Jason Ryan to Join Sema4 Board of Directors

Sema4, a patient-centered health intelligence company leveraging AI and machine learning to derive data-driven insights, today announced the appointment of renowned executive Jason Ryan to its Board of...

FMI : 136.95 (-0.04%)
CMLF : 11.60 (-7.05%)
MGTA : 6.97 (-3.73%)
RHHBY : 47.2000 (+0.94%)
OMIC : 16.07 (-7.67%)
NVTA : 26.54 (-3.88%)
TWST : 109.39 (-4.88%)
3 Reasons to Invest in Regeneron Pharmaceuticals (REGN) Now

Regeneron's (REGN) efforts to expand the label of its approved drugs and concurrently develop the pipeline are impressive and makes it a good bet for investors, for now.

REGN : 575.63 (-0.37%)
SNY : 51.52 (-0.21%)
RHHBY : 47.2000 (+0.94%)
BAYRY : 14.8840 (-1.57%)
Merck (MRK) to Withdraw a Gastric Cancer Indication for Keytruda

Merck's (MRK) Keytruda is approved under FDA's accelerated pathway for recurrent gastric or gastroesophageal junction adenocarcinoma indication but fails in post-marketing commitment study.

GSK : 39.53 (+1.31%)
RHHBY : 47.2000 (+0.94%)
MRK : 77.70 (+0.60%)
AMGN : 244.09 (-0.40%)

Barchart Exclusives

China Attempts to Stabilize Prices- Metals Prices Bounce- Rising Energy Prices Increase The Production Cost- This Week In Metals
This week we look at China's efforts to keep a lid on metals prices and how rising energy prices are making it more expensive to mine and refine the metals that are the building blocks for infrastructure building and rebuilding. Q2 earnings for Steel Dynamics and Nucor exceeded expectations. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar